Arrowhead net loss widens to $194.28 million in FY26 Q3; revenue rises to $75.25 million - ARWR News | RalliesArrowhead net loss widens to $194.28 million in FY26 Q3; revenue rises to $75.25 million
A
ARWR• Program updates
- REDEMPLO prescriptions roughly doubled; plozasiran Phase 3 SHASTA-3/4 met endpoints with 79%-81% median triglyceride reductions.
Fiscal Q3 results and cash position
- Arrowhead posted fiscal 2026 Q3 revenue of USD 75.25 million, up 170.99% year over year.
- Net loss attributable to shareholders widened to USD 194.28 million; diluted loss per share deepened to USD 1.36.
- R&D expense climbed to USD 198.22 million; SG&A rose to USD 47.12 million.
- Total cash resources increased to USD 1.57 billion as of June 30, 2026.
•
